Citi Pharma (KAR:CPHL) EV-to-Revenue : (As of Jun. 08, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Citi Pharma's enterprise value is ₨6,625.38 Mil. Citi Pharma does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Citi Pharma's EV-to-Revenue at this moment.

The historical rank and industry rank for Citi Pharma's EV-to-Revenue or its related term are showing as below:

KAR:CPHL's EV-to-Revenue is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.255
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-08), Citi Pharma's stock price is ₨29.00. Citi Pharma does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Citi Pharma's PS Ratio at this moment.

Citi Pharma EV-to-Revenue Historical Data

The historical data trend for Citi Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma EV-to-Revenue Chart

Citi Pharma Annual Data

Trend

EV-to-Revenue

Citi Pharma Semi-Annual Data

EV-to-Revenue

Competitive Comparison of Citi Pharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Citi Pharma's EV-to-Revenue falls into.

Citi Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Citi Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	6625.375	/
	=

Citi Pharma (KAR:CPHL) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Citi Pharma's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	29.00	/
	=

Citi Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Citi Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Citi Pharma (KAR:CPHL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

588 Q Block, Johar Town, Lahore, PB, PAK

Website

http://www.citipharma.com.pk

Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma (KAR:CPHL) Headlines

No Headlines